Michael James Lukey
Cancer Center Member
Ph.D., University of Oxford, U.K., 2010
firstname.lastname@example.org | 516-367-5016Faculty Profile
Tumor growth depends upon cancer cells acquiring nutrients from their environment and using these molecules to fuel proliferation. My group studies the nature and regulation of metabolic adaptation during tumorigenesis and metastasis, with the intention of identifying metabolic vulnerabilities that can be targeted for cancer therapy.
Proliferative signals in mammalian cells drive biosynthetic programs that support cell growth and replication. In healthy cells this process is tightly regulated by growth factors, but in cancer cells oncogenic lesions can result in continuous signaling to the metabolic machinery. Oncogene-driven metabolic reprogramming supports tumorigenesis but renders cells sensitive to specific metabolic stresses, a phenomenon that is exploited for cancer therapy. Because the distribution of nutrients varies markedly between organs, cancer cells growing at different sites in the body – and in different regions of the tumor microenvironment—must employ a range of metabolic strategies to fuel their growth. We aim first to understand the nature and regulation of metabolic adaptations in the different stages of cancer, and then to develop therapeutic strategies that target resulting vulnerabilities. We are especially interested in the biochemical processes underlying nutrient sensing and metabolic/redox homeostasis, including regulation of the protein post-translational modification landscape by reactive metabolites. We are also exploring the reciprocal connections between tumor metabolism and host physiology, recognizing that metabolic therapies must be designed to synergize with, and not to antagonize, the anti-tumor immune response.
METAvivor Early Career Investigator Award Jan. 2020 – present
Breast Cancer Coalition of Rochester Research Award April 2017 – April 2018
A new, sustainable source for a promising cancer killer
March 23, 2023
This Malaysian jungle plant produces a chemical with remarkable anticancer properties. Now, CSHL scientists can synthesize that chemical in the lab.
How cancer metabolism could be key for new therapies
February 5, 2020
Assistant Professor Michael Lukey joins the CSHL faculty, studying metabolic reprogramming events in cancer.
Inhibition of mitochondrial metabolism by (-)-jerantinine A: synthesis and biological studies in triple-negative breast cancer cells.
26 Apr 2023 | MedChemComm | 14(4):710-714
Gialelis, Timothy, Wang, Zifei, Homer, Joshua, Yang, Wen-Hsuan, Chung, Taemoon, Hu, Qingting, Smedley, Christopher, Pawar, Nitin, Upadhyay, Nitinkumar, Tuveson, David, Lyons, Scott, Lukey, Michael, Moses, John
Ketogenic diet promotes tumor ferroptosis but induces relative corticosterone deficiency that accelerates cachexia.
18 Feb 2023 | bioRxiv
Ferrer, Miriam, Mourikis, Nicholas, Davidson, Emma, Kleeman, Sam, Zaccaria, Marta, Habel, Jill, Rubino, Rachel, Flint, Thomas, Connell, Claire, Lukey, Michael, White, Eileen, Coll, Anthony, Venkitaraman, Ashok, Janowitz, Tobias
Early Neutrophilia Marked by Aerobic Glycolysis Sustains Host Metabolism and Delays Cancer Cachexia
1 Feb 2022 | Cancers | 14(4):963
Petruzzelli, M, Ferrer, M, Schuijs, M, Kleeman, S, Mourikis, N, Hall, Z, Perera, D, Raghunathan, S, Vacca, M, Gaude, E, Lukey, M, Jodrell, D, Frezza, C, Wagner, E, Venkitaraman, A, Halim, T, Janowitz, T
Enhancing the Efficacy of Glutamine Metabolism Inhibitors in Cancer Therapy.
18 May 2021 | Trends in Cancer
Yang, Wen-Hsuan, Qiu, Yijian, Stamatatos, Olivia, Janowitz, Tobias, Lukey, Michael
Lysine succinylation and SIRT5 couple nutritional status to glutamine catabolism.
19 Mar 2020 | Molecular and Cellular Oncology | 7(3):1735284
Lukey, M, Greene, K, Cerione, R
SIRT5 stabilizes mitochondrial glutaminase and supports breast cancer tumorigenesis
16 Dec 2019 | Proceedings of the National Academy of Sciences of USA
Greene, K, Lukey, M, Wang, X, Blank, B, Druso, J, Lin, M, Stalnecker, C, Zhang, C, Negron Abril, Y, Erickson, J, Wilson, K, Lin, H, Weiss, R, Cerione, R
Liver-Type Glutaminase GLS2 Is a Druggable Metabolic Node in Luminal-Subtype Breast Cancer
1 Oct 2019 | Cell Reports | 29(1):76-88 e7
Lukey, M, Cluntun, A, Katt, W, Lin, M, Druso, J, Ramachandran, S, Erickson, J, Le, H, Wang, Z, Blank, B, Greene, K, Cerione, R
Starving the Devourer: Cutting Cancer Off from Its Favorite Foods
19 Sep 2019 | Cell chemical biology | 26(9):1197-1199
Katt, W, Lukey, M, Cerione, R
Lipid-filled vesicles modulate macrophages
1 Mar 2019 | Science | 363(6430):931-932
Antonyak, M, Lukey, M, Cerione, R
Targeting Therapy Resistance: When Glutamine Catabolism Becomes Essential
14 May 2018 | Cancer Cell | 33(5):795-797
Lukey, M, Katt, W, Cerione, R